Townsend, Natasa C. MD*; Huth, Bradley J. MD*; Ding, William MD*; Garber, Bruce MD, FACS*; Mooreville, Michael MD, FACS†; Arrigo, Stephen MD‡§; Lamond, John MD‡§; Brady, Luther W. MD*‡
Prostate cancer is the most common noncutaneous cancer in men, with an estimated 186,000 cases diagnosed in 2008 according to the National Cancer Institute.1 It is the second leading cause of cancer-related deaths (∼30,000/y).1 The absolute number of prostate cancer deaths has been steadily decreasing, which can be attributed to early detection because of the use of the prostate-specific antigen (PSA) screening test and the transrectal ultrasound-guided extended pattern biopsy.
Recent analysis of the radiobiological properties of the prostate tumors suggests that their alpha/beta ratio may be as low as 1.5 Gy,2–4 indicating that they are more sensitive to higher doses of radiation per fraction. This low ratio is the rationale for hypofractionation of definitive therapy (fewer number of fractions), resulting in an attractive treatment option with respect to treatment duration and logistics. Retrospective evidence further supports the fact that prostate cancer treatment can be achieved via a hypofractionated regimen. Retrospective studies from the United Kingdom5 show that men who were treated between the 1960s and the1980s with a hypofractionated regimen because of lack of machine availability achieved results comparable to those from other reported series.6–10 A more contemporary report of the UK experience confirms that hypofractionation is feasible and results in low bladder and rectal toxicities.11 Other prospective single-arm and randomized trials support the idea that a hypofractionated regimen for the treatment of prostate cancer is feasible.12,13
Radiation therapy for treatment of prostate cancer has evolved over the years, with the goal being to achieve high conformality to the prostate whereas avoiding surrounding sensitive tissues such as the bladder and rectum. High-dose rate (HDR) brachytherapy has gained popularity and has been used either as monotherapy in patients with low-risk prostate cancer or as a boost after intensity-modulated radiation therapy (IMRT) in patients with intermediate- to high-risk prostate cancer.14,15 HDR brachytherapy is, however, an invasive procedure with the associated risks of infection, bleeding, and reactions to anesthesia. It has been shown that HDR dosimetry can be closely replicated in a minimally invasive manner with the use of stereotactic body radiation therapy (SBRT).16 One platform that delivers SBRT is the CyberKnife System (Accuray, Inc, Sunnyvale, CA). It consists of a 6-MV linear accelerator mounted on a robotic arm capable of moving within 6 degrees of freedom (independent linear and rotational motion, in the direction of, and about each of the 3 three-dimensional axes, x, y, z). In contrast, most conventional linear accelerators have 3 degrees of freedom to account for patient or target motion (3 degrees of freedom—linear motion: in/out, up/down, and left/right). A unique feature of the CyberKnife is its ability to track the motion of the prostate in real time during radiation treatment by imaging the positions of 3 to 4 gold fiducial seeds placed in the prostate prior to treatment planning. Depending on the motion of the prostate, the machine automatically repositions the robotic arm-mounted linear accelerator in response to variations in target position and delivers 100 to 200 noncoplanar pencil beams to the prostate, limiting the dose to the surrounding tissues. The radiation treatment is delivered in a hypofractionated regimen: The total dose is low relative to the conventional dose, but the dose per fraction is increased so the biologic effect to the tumor may be greater. In this article, we assess the acute gastrointestinal (GI) and genitourinary (GU) toxicities in 48 men with prostate cancer treated with the CyberKnife.
MATERIALS AND METHODS
A retrospective chart review was performed for the first 50 patients treated with CyberKnife external beam radiation therapy between October 2006 and August 2008. Two of 50 patients had metastatic disease at presentation and were excluded from the study. The remaining patients had T1–T3 prostate cancer. The median age was 66 years, with a range of 46 to 80 years. All patients had a diagnosis of prostate adenocarcinoma, which was confirmed by biopsy. Their pretreatment PSA values ranged from 0.13 to 59.6 ng/mL (normal range, 0–4 ng/mL), with mean and median values of 9.34 and 6.05 ng/mL, respectively. The mean Gleason score was 7. Of the 48 patients, 16 did not have any reported comorbidities, and the remainder had a history of at least one other comorbidity including hypertension, coronary artery disease, obesity, and smoking. Twelve patients received hormone therapy. Patient and tumor characteristics are summarized in Table 1.
The initial patient consultation consisted of a detailed history, with special attention to baseline GI and GU symptoms (Table 2) and a physical examination. Patient preparation prior to treatment included placing fiducial markers into the prostate and creating a custom-fit body mold to minimize movement during treatment. All patients had thin-cut (1.5 mm) planning CT, and/or thin-cut (1.5 mm) planning MRI, to outline the clinical target volume (CTV) with margins to generate the planning target volume (PTV). The CTV included the prostate gland only, and the PTV consisted of CTV with a 5 mm margin in all directions except in the posterior of the gland, where a margin of 3 mm was used. In the majority of cases, the urethra was neither visualized nor contoured, and was included in the CTV. The seminal vesicles were not contoured, and were therefore not included in the PTV. The mean PTV was 83 cm3 with a range of 21 to 243 cm3.
Treatment planning was done by the inverse planning technique, with the goal to achieve high conformality with rapid dose fall-off away from the target. The dose was prescribed to the PTV with ≥97% coverage, and an isodose line of 85% with a maximum dose of 115%. The maximum rectal dose was limited to 1 cm3 receiving <36 Gy and 50% of the volume receiving <50% of the prescribed dose. The bladder was limited to 10 cm3 receiving <37 Gy.
A total of 37 patients were treated exclusively with the CyberKnife for 5 fractions of 7 to 7.5 Gy/fraction, to a total dose ranging from 35 to 37.5 Gy. Assuming an alpha/beta ratio of 1.5 Gy, this regimen delivered an equivalent dose of 85 to 96 Gy in 2 Gy fractions (EQD2). The remaining 11 patients received other forms of treatment (IMRT; Tomotherapy, TomoTherapy Inc, Madison, WI) and subsequently received a boost to the prostate via the CyberKnife. Of 11 patients 8 received a boost in 2 fractions, ranging from 8.8 to 10.5 Gy/fraction (EQD2 = 51.8–72 Gy, assuming alpha/beta 1.5 Gy). Two patients received a boost in 5 fractions of 5 Gy/fraction (EQD2 = 46.4 Gy), and 1 patient received a boost of 8 Gy/fraction in 3 fractions (EQD2 = 65 Gy). These variations were the result of the individual preferences of the attending radiation oncologists who favored lower doses per fraction for larger prostate volumes. Doses received are summarized in Table 3.
The acute toxicities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0,17 which were measured throughout treatment and up to 24 weeks postradiation. The follow-up visits were scheduled between 4 and 24 weeks after the end of treatment. The mean and median follow-up times were 12 and 11.5 weeks, respectively. The highest symptom score, which was obtained either during treatment or at follow-up visits, was used to record the acute toxicities. The mean post-treatment PSA value was 2.41 ng/mL at a mean follow-up time of 12 weeks. However, only 28 patients had PSA results for the follow-up visits.
All 48 patients completed the treatments. As mentioned previously, Table 2 summarizes the pretreatment symptoms and post-treatment acute GU and GI toxicities, according to the CTCAE scale. The highest toxicity score for each patient was used to calculate the CTCAE value. Nine patients were free of both pretreatment GU and GI symptoms, and most of the symptoms experienced by other patients before treatment were those of frequency, urgency, and nocturia. Three patients experienced pretreatment GU symptoms equivalent to CTCAE grade 2, one of which was attributed to the patient's long history of BPH and incontinence.
Eight patients either did not complain of any GU or GI symptoms post-treatment or complained of a mild increase in frequency/nocturia (but less than twice normal frequency). Acute grade 1 GU and GI toxicities were found in 54% and 10% of patients, respectively. Acute grade 2 GU toxicities were found in only 10% of patients and included symptoms of frequency/nocturia and dysuria because of epididymitis from fiducial placement. Acute grade 3 GU toxicities were reported by 8% of patients and included symptoms such as frequency, nocturia, and dysuria. No grade ≥2 GI toxicity was seen. Table 2 also separates the post-treatment symptoms by the patient treatment group (CyberKnife monotherapy vs. CyberKnife boost to prostate). It can be seen that about a third of patients in the boost group experienced grade ≥2 GU symptoms, and no one in the boost group experienced any GI symptoms. In general, the majority of side effects were in the form of GU toxicities for both treatment groups, and highest toxicity scores were recorded immediately after or within 1 month of treatment. However, most symptoms returned to baseline within a 3-month period.
In a hypofractionated regimen, however, the development of late toxicities may be increased. These patients will be included in a longer study to analyze the potential late toxicities and treatment efficacy.
Acute toxicities were compared with those resulting from 3-dimensional conformal radiation therapy (3D-CRT), IMRT, HDR brachytherapy, and SBRT. These results are summarized in Table 4. Caution should be used when comparing the data from different facilities and investigators because the toxicity scales and the use of medications to treat the symptoms may vary. Additionally, toxicity recordings include a degree of subjectivity because the descriptions of toxicities are not precise.
Three-dimensional conformal therapy reports showed a higher overall rectal and grade ≥2 urinary morbidity. Michalski et al18 reported acute toxicities for 219 patients. The patients were stratified into 2 categories on the basis of the risk of seminal vesicle invasion and were treated with 2 Gy fractions to a total of 78 Gy to the prostate only or 54 Gy to prostate + seminal vesicle and a boost to the prostate to 78 Gy. The authors reported overall GU and GI grade ≥2 toxicity in 40% and 47% of patients, respectively.
Zietman et al6 randomized 393 patients to receive either a conventional dose of 70.2 Gy or an escalated dose of 79.2 Gy using a combination of conformal photon and proton beams. They used the Radiation Therapy Oncology Group (RTOG) toxicity criteria and reported 48% and 50% grade ≥2 GU and GI toxicities, respectively. Peeters et al7 reported results from a multicenter randomized trial. A total of 669 patients were randomized to receive 68 or 78 Gy to either the prostate alone or the prostate + seminal vesicle and showed grade ≥2 being at least 47% for GU and at least 50% for GI morbidity.
The IMRT reports show reduced or comparable results for acute GU and GI toxicities. Zelefsky et al8 reported acute toxicities in 772 patients with prostate cancer treated with high-dose IMRT (81–86.4 Gy) and found that the incidence of acute rectal toxicity was reduced compared with that observed with conventional 3D-CRT. The same report mentions that the incidence of acute urinary symptoms was not significantly different from those reported in previous studies.
De Meerleer et al9 used the RTOG scale to record the acute toxicity after IMRT in 114 patients. They found grade 1 and grade 2 rectal toxicity to be 44% and 29%, respectively, leaving about 35% without rectal symptoms. They reported grade 1 and grade 2 GU toxicity to be at 47% and 36%, respectively.
Lim et al10 conducted a prospective phase I study of 66 high-risk patients who had hypofractionated accelerated radiotherapy, with a concomitant IMRT boost and elective pelvic nodal radiation. They assessed acute toxicities according to the CTCAE, version 3.0 criteria; they found that only 5 patients reported grade 3 GU acute toxicity and no patients had grade 3 or greater GI acute toxicity.
In a retrospective study from Japan, Yoshioka et al19 reported acute toxicities after HDR brachytherapy as monotherapy for 43 patients, mostly from intermediate to high-risk categories. They treated the patients in 8 or 9 fractions at 6 Gy/fraction and assessed toxicities using the RTOG criteria. Five percent of patients complained of grade ≥2 GI toxicity and 25% of patients reported grade ≥2 GU toxicity. However, only 55% of patients had no biochemical evidence of disease.
Corner et al20 completed a phase II HDR brachytherapy as a monotherapy study in which they treated 110 patients in 3 or 4 fractions to a total of 31.5 to 36 Gy. Both GU and GI acute toxicities peaked about 2 weeks after treatment but started to decline and were almost back to baseline by 12 weeks after treatment.
Several SBRT exist that suggest a tolerable acute toxicity profile. Madsen et al21 reported acute toxicities for 40 patients treated in 5 fractions to a total dose of 33.5 Gy. The acute toxicities were assessed through American Urological Association and common toxicity criteria. Twenty-one percent and 13% of patients reported grade ≥2 GU and GI toxicities, respectively.
King et al22 reported preliminary results from a phase II clinical trial for 41 patients treated with the CyberKnife hypofractionated regimen in 5 fractions to a total dose of 36.25 Gy. They assessed toxicities using the International Prostate Symptom Score and RTOG criteria and reported a favorable acute toxicity profile.
In general, the acute toxicities established in our study were more frequent for GU than for GI symptoms, similar to what has been reported in the literature for IMRT.8–10 Additionally, the results from our study show that most CTCAE grade ≥2 results for both GU and GI symptoms were comparable to or lower than those that have been reported for either IMRT or 3D-CRT and HDR brachytherapy.6,7,18–20 Roughly about a third to a half of patients experienced grade ≥2 toxicity in both IMRT and 3D-CRT studies, whereas that percentage in our study is lower. However, the percentage of patients experiencing GU grade 1 toxicity in this study is comparable to those reported in the literature.6–9,18–20
Some of the limitations of this study are the retrospective nature of the project, the small number of patients, and the variations in dose and fractionation schedules (especially in the boost-to-prostate subset). The data gathered only support the acute toxicity data because of the short follow-up time. To date, with the median follow-up period of 12 weeks, the mean PSA value has decreased from 9.34 to 2.41 ng/mL; however, only 28 patients completed PSA testing post-treatment. With the hypofractionated regimen, one has to be careful about assessing the late toxicities; therefore, a longer follow-up period is needed to determine both the development of late toxicities and the treatment efficacy.
In general, patients who presented with symptoms before radiation treatment had a slight increase in the severity of their symptoms, and most of them returned to baseline within 6 to 8 weeks after treatment. The use of CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer shows promising results in terms of acute toxicity profiles. However, larger, prospective randomized studies with a longer follow up are desirable to confirm this result.
2. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13.
3. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101.
4. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021–1031.
5. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol). 1991;3:127–132.
6. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239.
7. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034.
8. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116.
9. De Meerleer G, Vakaet L, Meersschout S, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys. 2004;60:777–787.
10. Lim TS, Cheung Patrick CF, et al. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys. 2008;72:85–92.
11. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57:1254–1259.
12. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63:1463–1468.
13. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64:518–526.
14. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316.
15. Vargas CE, Martinez AA, Boike TP, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys. 2006;66:416–423.
16. Fuller DB, Naitoh J, Lee C, et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008;70:1588–1597.
18. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 2005;62:706–713.
19. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys. 2003;56:213–220.
20. Corner C, Rojas AM, Bryant L, et al. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:441–446.
21. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105.
22. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043–1048.